HDAC2 and cancer: The hypothesis that the effect of HDACi against cancer rely on unimpaired immune capabilities, together with our findings that HDAC2 overexpression in AML leads to repression of MHC class II genes, strongly indicates that levels of HDACs and in particular of HDAC2 might impact on HDACi response in vivo and should be taken into consideration as a cause of possible resistance.